Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …

Objectives The objective of this trial was to investigate the safety and preliminary
effectiveness of a daily dose of 300 mg of tenofovir disoproxil fumarate (TDF) versus placebo …

Although pre-exposure prophylaxis (PrEP)—the use of antiretroviral drugs by non-infected
people to prevent the acquisition of HIV—is a promising preventive option, important public …

Background. Recent trials report the short-term efficacy of tenofovir-based pre-exposure
prophylaxis (PrEP) for prevention of human immunodeficiency virus (HIV) infection. PrEP's …

Background Antiretroviral therapy (ART) during pregnancy is important for both maternal
health and prevention of perinatal HIV-1 transmission; however adequate data on the safety …

Background Simplified regimens for the treatment of human immunodeficiency virus type 1
(HIV-1) infection may increase patient satisfaction and facilitate adherence. Methods In this …

Pre-exposure prophylaxis (PrEP) is a promising intervention to prevent HIV acquisition, with
benefits both to the individual and to population-level health. PrEP is an opportunity to …

Abstract Introduction Oral HIV Pre‐Exposure Prophylaxis (PrEP) with tenofovir (TFV)
disoproxil fumarate (TDF)/emtricitabine (FTC) is highly effective. Transgender women (TGW) …

Background Long-acting injectable regimens may simplify therapy for patients with human
immunodeficiency virus type 1 (HIV-1) infection. Methods We conducted a phase 3 …

Background The relative feasibility and acceptability of daily versus non-daily dosing of oral
HIV pre-exposure prophylaxis (PrEP) among women are unknown. We aimed to investigate …